Hycamtin Injection, Powder, Lyophilized, For Solution
Product Images NDC 0078-0674

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Hycamtin (NDC 0078-0674). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Topotecan Hydrochloride Chemical Structure (Hycamtin Injection Spl Graphic 01)

Topotecan Hydrochloride Chemical Structure (Hycamtin Injection Spl Graphic 01)
Chemical structure of topotecan hydrochloride, the active ingredient in HYCAMTIN injection. The structure depicts the molecular arrangement with characteristic rings and functional groups, including hydrochloride. This diagram is used in the product labeling for the 4 mg/4 mL lyophilized powder for intravenous solution by Novartis Pharmaceuticals Corporation.*
FDA Label Image

Figure 1. Overall Survival Curves Comparing Hycamtin Plus Cisplatin Versus Cisplatin Monotherapy In Cervical Cancer Patients (Hycamtin Injection Spl Graphic 02)

Figure 1. Overall Survival Curves Comparing Hycamtin Plus Cisplatin Versus Cisplatin Monotherapy In Cervical Cancer Patients (Hycamtin Injection Spl Graphic 02)
A survival curve comparing the proportion surviving over months on study between two groups: HYCAMTIN plus Cisplatin versus Cisplatin Monotherapy. The y-axis represents the proportion surviving from 0 to 1, and the x-axis represents months on study from 0 to 40. The graph includes a risk table showing the number of subjects at risk at various time points for each treatment group.*
FDA Label Image

Hycamtin Injection Label (Hycamtin Injection Spl Graphic 03)

Hycamtin Injection Label (Hycamtin Injection Spl Graphic 03)
Packaging label for HYCAMTIN 4 mg injection powder, lyophilized for solution, containing topotecan hydrochloride. The label indicates a single-dose vial for intravenous use. The product is distributed by Novartis Pharmaceuticals Corporation and made in Ireland. Storage instructions and dosage information notes are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.